NCT06714383View on ClinicalTrials.gov

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

November 30, 2025

Conditions
Osteosarcoma
Interventions
DRUG

Trilaciclib

Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.

DRUG

Pirarubicin

Pirarubicin: 60 mg/m2，IV，d1-2

DRUG

Lobaplatin

LobaplLatin: 40 mg/m2,，IV，d1

Trial Locations (1)

100000

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER